Significant Ownership of TCG Crossover GP I, LLC

Large-stake snapshot 1 signal
Large-stake filing summary
  • Recent SEC Schedule 13D/G filings for TCG Crossover GP I, LLC focus on large-stake beneficial ownership disclosures and amendments.
  • Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
Manager Names, identifiers, and filing context for this profile. 2 identity fields
Manager signature
/s/ Craig Skaling - Craig Skaling, Authorized Signatory
Manager location
Palo Alto, CA

Follow Filing Activity

Follow TCG Crossover GP I, LLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.

Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.

Review Pro alert access Already have an account? Sign in and return here

Significant Ownership of TCG Crossover GP I, LLC

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
ABVX Abivax SA Ordinary Shares, par value Euro 0.01 per share 7% $816,945,267 -$150,089,557 6,007,834 -16% Chen Yu 30 Jun 2026
VTGN Vistagen Therapeutics, Inc. Common Stock, par value $0.001 per share 6.7% $740,101 2,960,404 Chen Yu 30 Jun 2026
SVRA Savara Inc. Common Stock, $0.001 par value per share 6.1% $73,184,254 12,362,205 TCG Crossover GP I, LLC 31 Dec 2025
TYRA Tyra Biosciences, Inc. Common Stock, par value $0.0001 per share 5.7% $29,792,499 2,898,103 TCG Crossover GP I, LLC 27 Feb 2025
CGON CG Oncology, Inc. Common Stock, par value $0.0001 per share 4.8% $102,655,662 3,670,206 TCG Crossover GP I, LLC 31 Mar 2025
COGT Cogent Biosciences, Inc. Common Stock, par value $0.001 per share 4.8% $97,621,606 6,798,162 TCG Crossover GP I, LLC 30 Sep 2025
UPB Upstream Bio, Inc. Common Stock, par value $0.001 per share 3.9% $39,822,919 -$12,878,523 2,117,103 -24% TCG Crossover GP I, LLC 30 Sep 2025
CMPS COMPASS Pathways plc Ordinary Shares, nominal value 0.008 per share 3.9% $14,197,440 3,858,000 Chen Yu 30 Jun 2025
TRDA Entrada Therapeutics, Inc. Common Stock, par value $0.0001 per share 2.7% $7,803,293 -$6,308,359 1,060,230 -45% TCG Crossover GP I, LLC 30 Jun 2026
JBIO Jade Biosciences, Inc. Common Stock, $0.0001 par value per share 0.2% $649,193 64,023 TCG Crossover GP I, LLC 28 Apr 2025
ANTX AN2 Therapeutics, Inc. Common Stock, $0.00001 par value 0% $0 0 TCG Crossover GP I, LLC 31 Dec 2024

Schedules 13D/G Reported by TCG Crossover GP I, LLC:

Sym Target Class Ownership Change Current shares Change Value Reporting name Form Report period Filing date
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .